Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)

NCT01418430 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)

Interventions

DRUG: CHOP-daclizumab

Sponsor

King's College Hospital NHS Trust